Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease

Neurology

Volumn 77, Issue 15, 2011, Pages 1487-1493

  Karlawish, Jason ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; FLORBETAPIR F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; CLINICAL RESEARCH; COGNITIVE DEFECT; CONCEPTUAL FRAMEWORK; DAILY LIFE ACTIVITY; DISABILITY; ELDER ABUSE; EVIDENCE BASED MEDICINE; GENETIC SCREENING; GENOTYPE; HEALTH CARE POLICY; HEALTH EDUCATION; HIGH RISK PATIENT; HUMAN; MEDICAL ETHICS; MEDICAL INFORMATION; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PROFESSIONAL SECRECY; RISK ASSESSMENT;

EID: 82955235703     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318232ac1a     Document Type: Article

References (43)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944. (Pubitemid 14076461)
2. De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010;67:949-956.
3. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA 2011;305:275-283.
4. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011;7: 280-292.
5. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-1127.
6. Alzheimer Disease International. World Alzheimer Report 2010: The Global Economic Impact of Dementia. London, UK: Alzheimer Disease International; 2010.
7. Alzheimer's Association. 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010;6:158-194.
8. S. 3036: National Alzheimer's Project Act of 2011: 111th Congress: Second Session (2011).
9. Vickers AJ, Basch E, Kattan MW. Against diagnosis. Ann Intern Med 2008;149:200-203.
10. Karlawish J. Desktop medicine. JAMA 2010;304:2061-2062.
11. National Institutes of Health, National Heart, Lung, and Blood Institute. National Cholesterol Education Program: Program Description. Available at: http://www.nhlbi.nih.gov/about/ncep/ncep-pd.htm. Accessed January 26, 2011.
12. National Cholesterol Education Program (NCEP). Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Risk Assessment Tool for Estimating 10-year Risk of Developing Hard CHD (Myocardial Infarction and Coronary Death). Available at: http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof. Accessed June 8, 2010.
13. Metlife Foundation. MetLife Foundation Alzheimer's Survey: What America Thinks. New York: Metlife Foundation; 2006.
14. Pinker S. My genome, my self. New York Times. January 11, 2009: Sect. MM24.
15. Schneider LS. Organising the language of Alzheimer's disease in light of biomarkers. Lancet Neurol 2010;9:1044-1045.
16. Venter JC. A Life Decoded: My Genome: My Life. New York, NY: Viking; 2007.
17. Kolata G. Tests detect Alzheimer's risks, but should patients be told? New York Times. December 18, 2010: Sect. A1.
18. Kolata G. FDA sees promise in Alzheimer's imaging drug. New York Times. January 21, 2011: Sect. A1.
19. 23andMe, Inc. Alzheimer's Disease: Genetic Testing. Available at: https://www.23andme.com/health/alzheimers/. Accessed April 19, 2011.
20. Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009;361:245-254.
21. Roberts S, Linnenbringer E, Barber Butson M, et al. Impact of a condensed protocol for disclosing APOE genotype to first-degree relatives of people with Alzheimer's disease. Alzheimers Dement 2008;4:T454-T455. Abstract.
22. Szymaniak JM, Christensen KD, Uhlmann WR, Green RC, Roberts JS. A condensed genetic counseling approach for Alzheimer's disease susceptibility testing: what is the psychological impact? J Genet Couns 2009; 18:628. Abstract.
23. Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP. SPIKES: a six-step protocol for delivering bad news: application to the patient with cancer. Oncologist 2000;5:302-311. (Pubitemid 30666477)
24. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
25. Greene JA. The Abnormal and the pathological: cholesterols, statins, and the threshold of disease. In: Tone A, Siegel Watkins E, eds. Medicating Modern America: Prescription Drugs in History. New York: New York University Press; 2007:193-228.
26. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement 2011;7:270-279.
27. Expert Panel on Detection, Evaluation, and Treatment of High Blood, Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
28. Goozner M. Petition to the National Institutes of Health seeking an independent review panel to re-evaluate the National Cholesterol Education Program Guidelines. Available at: http://www.cspinet.org/new/pdf/finalnihltr. pdf. Accessed March 2, 2010.
29. Alving B. Petition to the National Institutes of Health seeking an independent review panel to re-evaluate the National Cholesterol Education Program Guidelines: reply. Available at: http://www.nhlbi.nih.gov/guidelines/ cholesterol/response.htm. Accessed March 2, 2010.
30. Brookmeyer R, Evans DA, Hebert L, et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement 2011;7:61-73.
31. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105.
32. Murphy K. Splits form over how to address bone loss. New York Times. September 8, 2009: Sect. D5.
33. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
34. Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician's Guide to prevention and treatment of osteoporosis and the WHO fracture risk assessment tool (FRAX): what they mean to the bone densitometrist and bone technologist. Int Soc Clin Densitometry 2008;11:473-477.
35. Donaldson MG, Cawthorn PM, Lui L-Y, et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation guidelines. J Bone Miner Res 2009;24:675-680.
36. Tuomilehto J, Wareham N. Glucose lowering and diabetes prevention: are they the same? Lancet 2006;268:1218-1219. (Pubitemid 44485774)
37. Rosenthal E. Drug can prevent diabetes in many at high risk, study suggests. New York Times. Available at: http:// www.nytimes.com/2006/09/17/ world/17diabetes.html. Accessed April 19, 2011.
38. Guyatt G, Akl EA, Hirsh J, et al. The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med 2010;152:738-741.
39. Schunemann HJ, Hill SR, Kakad M, et al. Transparent development of the WHO rapid advice guidelines. PLoS Med 2007;4:e119.
40. Sabatino CP. Damage prevention and control for financial incapacity. JAMA 2011;305:707-708.
41. Widera E, Steenpass V, Marson D, Sudore R. Finances in the older patient with cognitive impairment: "he didn't want me to take over." JAMA 2011;305:698-706.
42. Financial Industry Regulatory Authority. Senior Investor Suitability Considerations (EL-ELC134). Available at: http://www.finra.org/web/groups/ industry/@ip/@edu/documents/education/p121536.pdf. Accessed August 27, 2011.
43. National Conference of Commissioners on Uniform State Laws. Uniform Power of Attorney Act. Available at: http://www.law.upenn.edu/bll/archives/ulc/dpoaa/ 2008-final.htm. Accessed April 19, 2011.